Argade, Pallavi
Liquisolid Compact Tablet of Candesartan Cilexetil with Enhanced Solubility using Neusilin US2, Aerosil 200 and Transcutol HP - Vol.53(30, Jul-Sep - Karnataka Indian journal of pharmaceutical education and research 2019 - 457-467p.
Objective: An attempt was made to enhance solubility, dissolution and intestinal permeability of drug candesartan cilexetil by liquisolid technology. Methods: Liquisolid tablet was formulated using non-volatile solvent Transcutol HP, carrier material Neusilin US2 and coating material Aerosil 200. Appropriate quantities of excipients were calculated with the help of mathematical model to get liquisolid powder. A 32 full-factorial design was used further to optimize liquisolid powder. Results: DSC, XRD and SEM studies revealed absence of crystalline nature of drug in liquisolid powder. Liquisolid powder was further compressed into tablet and subjected to various evaluation tests such as in-vitro drug release and ex-vivo intestinal permeation study. Conclusion: Liquisolid technology was found to be promising due to enhance solubility, dissolution and permeation of candesartan cilexetil by 19.75, 3.09 and 2.4-fold, respectively.
PHARMACEUTICS
Liquisolid Compact Tablet of Candesartan Cilexetil with Enhanced Solubility using Neusilin US2, Aerosil 200 and Transcutol HP - Vol.53(30, Jul-Sep - Karnataka Indian journal of pharmaceutical education and research 2019 - 457-467p.
Objective: An attempt was made to enhance solubility, dissolution and intestinal permeability of drug candesartan cilexetil by liquisolid technology. Methods: Liquisolid tablet was formulated using non-volatile solvent Transcutol HP, carrier material Neusilin US2 and coating material Aerosil 200. Appropriate quantities of excipients were calculated with the help of mathematical model to get liquisolid powder. A 32 full-factorial design was used further to optimize liquisolid powder. Results: DSC, XRD and SEM studies revealed absence of crystalline nature of drug in liquisolid powder. Liquisolid powder was further compressed into tablet and subjected to various evaluation tests such as in-vitro drug release and ex-vivo intestinal permeation study. Conclusion: Liquisolid technology was found to be promising due to enhance solubility, dissolution and permeation of candesartan cilexetil by 19.75, 3.09 and 2.4-fold, respectively.
PHARMACEUTICS